1315
In the two cases, a combination of iloprost, a stable prostacyclin analogue (1 to 2 ng/kg/mn) with aspirin and dipyridamole was shown to inhibit ex vivo the heparin-induced platelet aggregation.
 ( potential therapeutic event: inhibit ex vivo ,  two cases: Subject, two: Subject.Population, iloprost, a stable prostacyclin analogue (1 to 2 ng/kg/mn) with aspirin and dipyridamole: Treatment, heparin-induced platelet aggregation: Treatment.Disorder, 1 to 2 ng/kg/mn: Treatment.Dosage, iloprost: Treatment.Drug, aspirin: Treatment.Drug, dipyridamole: Treatment.Drug, iloprost: Combination.Drug, aspirin: Combination.Drug, dipyridamole: Combination.Drug) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( potential therapeutic event: inhibit ex vivo ,  two cases: Subject, two: Subject.Population, iloprost, a stable prostacyclin analogue (1 to 2 ng/kg/mn) with aspirin and dipyridamole: Treatment, heparin-induced platelet aggregation: Treatment.Disorder, 1 to 2 ng/kg/mn: Treatment.Dosage, iloprost: Treatment.Drug, aspirin: Treatment.Drug, dipyridamole: Treatment.Drug, iloprost: Combination.Drug, aspirin: Combination.Drug, dipyridamole: Combination.Drug) 